Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.
Shanghai Henlius Biotech, Inc. has announced the successful completion of a phase 1 clinical study of its independently developed HLX15, a biosimilar of daratumumab, showing comparable pharmacokinetic, safety, and immunogenicity profiles to the original drug. HLX15 is intended for the treatment of multiple myeloma and aims to provide similar benefits to the current daratumumab treatments available in China, with sales volumes reaching approximately RMB852 million domestically and US$5.254 billion globally in 2023. Investors are cautioned as the company cannot guarantee the biosimilar’s future commercial success.
For further insights into HK:2696 stock, check out TipRanks’ Stock Analysis page.